SEN TED KENNEDY 1932-2009 RIP
August 26, 2009
According to recent news reports, the Federal Oncology Commission, headed by the Earle Warren Orchestra and Dr. Earle Warren on saxophone, will issue a report this morning that the immediate cause of Sen. Kennedy’s death was a lone cancer cell, acting alone, without the assistance of other cancer cells, and that any hint that the cancer cell acted in conspiracy or with the assistance of other cancer cells is silly and ridiculous.
Also, there were no cancer cells in the grassy knoll.
In heaping praise on the late Sen. Edward “Ted” Kennedy, let us not fall into the logical fallacy of overly admiring the ante-decedent Kennedies, and seeing the current Kennedy in their light, which would be an post-decedent ergo propter antedecedent hoc fallacy, or roughtly, the fallacy of denying the antedecedent.
Sen. Kennedy’s three older brothers were great men–joe jr. gave his life for his country in wwII, JFK was a great president, a princeton man who transferred to Harvard and graduated from there, and was known to have romanced the actresses gene tierney, marilyn monroe as well as his gorgeous wife jackie o, all in one spectacular lifetime, not to mention saying “ich bin ein Berliner.”
plus we all know that don draper wants to be JFK.
Bobby Kennedy had one best friend in the world other than jack, and that was Rosie Grier, a huge lineman who had gone to penn state with lennie moore and played on the fearsome foursome for the rams. rosie was not happy when bobby was gunned down in the ambassador hotel the night bobby won the california primary on national television.
so jack and bobby were martyrs, and teddy gave a beautiful eulogy, and about a month later mayor daley and lbj all but offered him the nomination, and he turned it down.
humphrey lost.
Kennedy set his sights on 1972, and nixon set his sights on ruining kennedy. nixon had the fbi watch him every minute.
meanwhile, ted kennedy got annoyed that jackie married ari onassis because he could only think how that would affect his own political prospects.
jackie told him where he could go with that one.
other errors of ted kennedy:
1) he destroyed the democratic party in 1979-1980 by running against pres. carter. this split opened the way for the reagan revolution, which in my view was a good thing, but it ended the 1932-1980 era of democratic party rule and began the 1980-2008 era of republican rule. it was a colossal error and misjudgment and an act of egotism on kennedy’s part.
2) he was negligent in the death of mary jo kopechne in 1969 at chappaquiddick. Mary Jo Kopechne was a girl from northeast pennsylvania, buried in forty fort, and no one in wilkes-barre scranton area ever forgave ted kennedy. america didnt forget.
3) he had a freshman take his spanish final for him at harvard. harvard instead of expelling him let him do two years in the army and reinstated him. he was later allowed to get his law degree at uva.
4) He was an alcoholic, and enabled his wife to become one too. as his ex-wife, joan has serious alcohol problems which have prevented her from being a proper mother to their kids.
5) he was a skirt-chasing adulterer. his circle of drunken skirt-chasers usually included sen moynihan, according to rumors.
6) he separated from joan in 1978, then reunited crassly in 1980 for his presidential run, fooling no one.
7) kennedy may have obstructed justice in the investigation of a rape case involving his nephew in florida in the early 1990s.
now there are many good things i can say about ted kennedy, but likewise, there are just as many bad.
he was a lot like nolan ryan, about half wins, half losses, and his fastball was great, but his wild pitches and walks would cost you ballgames, because the man was wild and had no self-control at all.
everything wrong with the democratic party was symbolized by ted kennedy–a liberal drunken divorcee, addicted to young women and booze, a drunk driver, reckless, not loyal to his own president, and egotistical.
also, he had no foreign policy views, which was really his achilles heel.
Unlike jfk, his older brother, who was an ardent anti-communist, ted kennedy was pretty much a blank on foreign policy issues. where jfk had concrete notions on handling russia and stopping communism and leading the military, ted kennedy’s only answer was to cut military spending and vote against every war every chance he got.
Kennedy also made sure the party nominated a string of northeast and massachussetts liberals-that had no chance of winning–because they were proxies for ted kennedy–when only a southerner could win such as al gore or bill clinton.
kennedy fomented a north-south, liberal-conservative split in his own party that kept it from winning the presidency for 8 out of 11 presidential elections, starting with 1980, but really going back to 1972, when kennedy backed mcgovern and 1976, when he was lukewarm over carter.
in short, he was not realistic, not a party man, and was 100% devoted to a liberal agenda that had passed the country by with the passing of the 1960s.
Ted Kennedy misapprehended the legacy of his own brother who was an ardent anti-communist, was pro-cia, pro-interventionist, anti-abortion, and even anti-birth control. even on civil rights, JFK and RFK were not as liberal as people think, at least back in 1962-63.
that’s why reagan was able to say, “i didn’t leave the democratic party, the democratic party left me”, a quip referring to the kennedy, liberal wing which had shifted to an anti-war, anti-american bias.
this created the reagan democrats, ethnic, blue collar, catholic and formerly jfk men and women, who now starting voting republican after 1980 and continuing thru to the obama election of 2008.
ted kennedy’s blind spot on his own brother’s views and legacy was a lasting weakness that marred his legacy.
regardless of how many laws he passed, he was never truly carrying the torch of the jfk legacy. that torch passed to LBJ and then onto Reagan a long, long time ago. bobby kennedy briefly had it but his flame was snuffed out in california that awful night in 1968 while rosie grier was standing next to poor bobby. bobby martin & john.
Abraham Martin & John by DION
Has anybody here seen my old friend Abraham,
Can you tell me where he’s gone?
He freed a lotta people, but it seems the good die young
But I just looked around and he’s gone.
Has anybody here seen my old friend John,
Can you tell me where he’s gone?
He freed a lotta people, but it seems the good die young
But I just looked around and he’s gone.
Has anybody here seen my old friend Martin,
Can you tell me where he’s gone?
He freed a lotta people, but it seems the good die young
But I just looked around and he’s gone.
Didn’t you love the things they stood for?
Didn’t they try to find some good for you and me?
And we’ll be free,
Someday soon it’s gonna be one day.
Has anybody here seen my old friend Bobby,
Can you tell me where he’s gone?
I thought I saw him walkin’ up over the hill
With Abraham, Martin and John
NEW LAST VERSE FOR TEDDY:
Has anybody here seen my old friend Teddy,
Can you tell me where he’s gone?
I thought I saw him walkin’ up over the hill
With Abraham, Martin, Bobby & John….
He freed a lotta people, but it seems the good they die young
But I just looked around and he was gone.
http://www.uulyrics.com/music/dion/song-abraham-martin-john/
–art kyriazis, philly/south jersey
home of the world champion phillies
COMENT ON TIME’S COVER STORY ON STEM CELL RESEARCH OF FEBRUARY 9, 2009
February 10, 2009
Time Magazine just did a cover story on stem cell research, which is commendable. They also entitled the story “The Quest Resumes,” which is commendable, focusing on the fact that the Federal Government, under the Obama Administration, may finally allow (this may already have been approved by executive order) federal funds for stem-cell research at federally funded research institutions.
However, the subtitle of the article is “After eight years of political ostracism, stem-cell scientists like Harvard’s Douglas Melton are coming back into the light—and making discoveries that may soon bring lifesaving breakthroughs.” Time Feb 9, 2009 at p. 36.
Now, let’s examine that for a second—In Massachusetts, where Prof. Melton plies his craft, the Commonwealth and State of Massachusetts, like the State of California, has voted state support of stem-cell research at institutions of higher education. Therefore in Massachusetts, like California a bastion of biotechnology, the biotech lobby was able to secure state support for stem-cell research during the eight-year long federal ban on such research. So compared to the other 48 states, Prof. Melton was actually at an advantage because his lab was in Massachusetts.
Because of the federal funds ban, a great deal of stem cell-research has begun to spring up in places like Southeast Asia, as the Time Magazine article correctly notes, and as it well-known in the biotech industry. But a lot of it is also staying put in Cali and Mass due to those states putting up seed money for biotech research that is stem cell oriented.
Next, Prof. Melton works as co-director of the Harvard Stem Cell Institute (HSCI), which Harvard has committed substantial resources to supporting over the past eight years and well into the future. According to their 2008 report, their annual spending has grown in the past two years from just over $5 million to over $16 million in fiscal year 2008, most of that culled from private and corporate donations. HSCI currently has no less than eight ongoing challenge grant research projects sponsored for $75,000 each, all of them stem cell oriented.
Now I am a powerful supporter of stem-cell research, and I strongly advocate that the federal government support stem cell research. The question I have for Time Magazine is, and maybe perhaps for the Federal Government, is HSCI the most needy recipient for federal funds for stem cell research? The article omits that HSCI is well-funded by private donors, and omits that Massachusetts provides state support (it is not clear if HSCI accepts Massachusetts money) and therefore the article in Time is somewhat misleading.
The argument for funding HSCI federally has to be this; we, e.g. HSCI, made a good faith effort to get the ball rolling the past three years through private financing, we have already a lab in motion with research projects, so if you fund us, we will be three years closer to getting results than any other academic lab you choose to fun. Consequently, their NIH grant requests will carry a certain heft.
On the other hand, they are not as dramatically in need of the money as some other labs who don’t have any private funding at all.
A more useful article would have been to depict the overall situation in the rest of the United States, and some of the labs outside CA & MA.
This is an interesting issue and one on which arguments on both sides would and could be marshalled.
It should be pointed out that I strongly support the work of Prof. Melton and the work of HSCI. Those initiatives were put into place by then President Lawrence Summers, along with the Broad Institute initiative, a few years back, and clearly they have had the effect of putting Harvard back on the map in terms of genetics and molecular biology research.
The good news about the Time article is that the words “Stem Cells” made the cover, along with a nice bio-photo. If nothing else, Americans this week can forget about the economy and the war for a moment and realize that stem cell research is an answer to many of our problems that don’t involve boundaries and account balances and fumes spewing out of our cars.
–art kyriazis philly/south jersey
home of the world champion phillies
T-CELL SCIENCES, INC. – CASE STUDY – WHARTON SCHOOL CASE STUDY – 1994 – Arthur J. Kyriazis University of Pennsylvania April 22, 1994
January 26, 2009
this is an actual case study I did at Wharton about fifteen years ago for Steve Sammut’s class on advanced patent portfolio management theory. This case is of interest because it concerns a biotech company, and because, re-reading it after a long time, it actually reads very well. Even before I had all the experience I do now, I actually had a good feel for what to do with the management of a biotech company even back then, so here it is. And yes, I did get an “A” in the class, of course. Dr. Sammut used to run the tech transfer office for Penn during the 1990s.
–art k
ps enjoy!
T-CELL SCIENCES, INC. CASE
by Arthur J. Kyriazis
MGMT 898 – PROF. SAMMUT
Wharton School (WEMBA)
University of Pennsylvania
April 22, 1994
Issues
T-Cell Sciences, Inc. (“T-Cell”) is a 1983 Cambridge, MA biotech/pharmaceutical startup sired by Patrick Kung, a “recognized pioneer in immunological research.” The main issue appears to be defining T-Cell’s ultimate market niche even as it undergoes the process of transition from a venture-funded start-up to a more mature publicly held corporation. Specifically, in the coming months and years, should T-Cell (1) concentrate upon basic across the board immunological R&D; (2) concentrate upon basic immunological R&D with a focus on diagnostic drugs and product(s); or (3) focus upon strategic alliances with large pharmaceutical companies with an eye cast towards the development and delivery of therapeutic pharmaceutical drugs?
It would appear that until the arrival of James D. Grant as CEO in November of 1986, the main issue might well have been a different one altogether, namely whether T-Cell would reorganize or liquidate. In early 1986, T-Cell was a company in trouble and one which was not being particularly well-run or well-managed, even though it had brilliant scientists and innovative technologies full of commercial promise. Even though startups might be expected to lose money at the outset, T-Cell’s losses in 1985 and 1986 totalled nearly $2 million, compared with $5.5 million capitalization from December of 1983 throught January of 1986. This apparently necessitated a public offering in May of 1986, which raised $11.1 million, followed by the hiring of Mr. Grant in November of 1986, and his hiring of a well-heeled financial CFO immediately thereafter.
In addition, up through Grant’s arrival, T-Cell had only developed two products of any consequence, ACT-T-SET, and CELLFREE, and only two joint venture/research alliances/R&D contracts of any consequence, the Syntex USA contract and the Pfizer contract, and had failed to show any revenue from product sales through 1986, and only $13 million in revenue from contracts in 1986.
In brief, one may surmise from the case study that a great deal of money was spent at T-Cell, until Grant’s arrival, on basic immunological research, without a very well defined sense of where the research was going, or how it would be profitable or generate a return to the company and to the investors. This might have been a result of Dr. Kung’s diffuse vision of the company’s market niche as somehow doing R&D better or faster, and perhaps a touch of the academic fondness for the intrinsic value of broad based academic research as opposed to targeted research and strategic alliances directed to product development and ultimate profit.
Grant’s arrival placed T-Cell on a radically different footing and he appears to have turned the company around. Losses were reduced by nearly a million dolars from 1986 to 1987, and for the year ending in April of 1987, T-Cell reported positive product sales revenue of nearly $400,000 together with contract revenues of nearly $2 million. In addition, Grant apparently negotiated the deal with Yamanouchi Parmaceutical, which as he characterizes it places T-Cell on a sound cash flow footing for the foreseeable future. In addition, Grant has introduced a sound line of command and professionalized the management of the company by hiring a financial officer and a regulatory affairs officer, paying attention to patent management issues, and spending time painting a sound, attractive picture to shareholders, potential investors and to regulators. Finally, Grant’s status an a former FDA head bodes well for the regulatory hurdles awaiting T-Cell’s products.
T-Cell’s Strengths
T-Cell’s strengths are many. First, it has a distinguished corps of researchers led off by Dr. Kung, who appears to be a leader in the field of T cell research. It is situated in Cambridge, MA, in the heart of the Harvard-MIT research community, and can be expected to easily draw upon an outstanding technical scientific staff for its research needs. Also, the scientific advisory board includes people like Dr. Mark Davis and others who are world-recognized scientific leaders.
Second, T-Cell has introduced two product lines in 1986, the ACT-T-SET and CELLFREE technologies, which assuming patent protection and FDA approval, are potentially product mainstays for the company. These two products are expected to have applicability in the diagnosis of various stages of immune system stimulation and white blood cell activity. Dr. Kung and Mr. Grant expect R&D to eventually identify other new products in the same T cell related vein with applicability in the diagnostic field.
Third, T-Cell has two joint ventures, with Syntex and Pfizer, and now a third, with Yamanouchi, which promise to focus on specific product development, with the obvious potential of delivering a drug to market which can be of wide therapeutic applicability and therefore be a cash mainstay for the company. The Syntex and Pfizer ventures aim to produce therapeutic drugs targeted at common medical ailments, including breast cancer, type 1 diabetes, rheumatoid arthritis and cytomegalovirus. The Yamanouchi venture aims to develop products to diagnose rheumatoid arthritis and lung cancer. An added benefit is the global ability to develop and market products and drugs in Japan and the rest of the world while awaiting FDA approval for their sale in the United States.
Fourth, T-Cell now has James D. Grant, who must be reckoned as an important asset of the company at this juncture. His management skills have put T-Cell on a sound business footing; his contacts have resulted in new joint venture(s); and his FDA expertise should translate into FDA product approvals.
Which Fields or Options are Most Attractive for T-Cell?
The basic R&D approach is wrong for this size company. What the company needs to do is ultimately make a decision between developing diagnostic products/drugs on its own, or on developing them with partners. Grant appears to be committed to a strategy of hedging his bets by pursuing both options. He is willing to commit some money to R&D and to diagnostics, while courting and signing deals with large pharmaceuticals for strategic alliance(s) aimed at delivering specific types of therapeutic products/drugs. Grant also feels that the diagnostic(s) division, once profitable, should be spun off because of the competition in that field.
Recommendations
Grant probably has it right. The therapeutic emphasis is the best way for T-Cell to go right now. The joint venture/strategic alliance approach is a sound one. If successful, the development of even one drug marketed to a patient population as widespread as the breast cancer or lung cancer populations promises immediate payoff for T-Cell’s efforts and a handsome reward for its investors.
With diagnostic drugs on the other hand, even if approved and even if proprietary, it is hard to see how T-Cell will be able to exploit the discoveries, so that Grant is probably correct when he surmises that this division or these proprietary discoveries will ultimately be spun off. Of course, licensing and franchising are options we have discussed which absent from Grant’s discussion(s).
The best way for T-Cell to go would be to continue to solicity these contracts and joint ventures. T-Cell has recognized, proven scientific talent and recognized expertise in this very specific area of immunological research.
One specific recommendation is that the company hire a patent portfolio manager and begin to concentrate on patenting more of its discoveries, as well as concentrate on getting products to FDA submission stage. This manager must also concentrate on getting the researchers to recognize when a discovery may or might be patentable or commerciable in some respect. These two steps will make the company attractive to investors and a steady stream of patent application(s) and FDA approval applications are evidence that a company has been doing its homework.
These steps, if followed, should result in a successful new round of equity financing and/or an invitation to buy the company out altogether. In either event, the company will have attained a substantial goal. Finally, T-Cell should keep Grant around. Given the company’s history, investors could get extremely nervous if he were to depart suddenly or unexpectedly.
–Arthur J Kyriazis, 1994
THIS WAS AN ACTUAL CASE STUDY I WROTE FOR THE WHARTON SCHOOL IN THE SPRING OF 1994.
–art kyriazis
Philly/South Jersey
Home of the World Champion Philadelphia Phillies
Home of the Incredible Philadelphia Eagles
Home of the Arena Football League Champion Philadelphia Soul
Making the Playoffs in 2008: The Sixers, the Flyers, the Phillies and the Eagles!
Happy New Year 2009

